|Day Low/High||20.80 / 21.60|
|52 Wk Low/High||19.25 / 24.00|
Billionaire Bill Ackman's recent appointment to the troubled drugmaker's board could signal a meanful change of direction.
Jim Cramer says the antitrust environment out there will make it difficult for any railroad mergers to be approved by regulators.
Investors are gearing up for another assessment of the global economy, as the Fed Prepares to release the minutes of its March meeting.
Jim Cramer says the merger between Pfizer and Allergan isn't going anywhere, as lawmakers try to limit corporate inversions.
TheStreet's Jim Cramer said Valeant Pharmaceuticals' (VRX) move to appoint billionaire investor Bill Ackman to the board of directors isn't enough and a government monitor is needed.
And four other things you need to know now.
But investors are likely to be wary ahead of the Fed meeting.
TheStreet’s Jim Cramer answers your Twitter questions from the floor of the New York Stock Exchange.
Deals coming fast and furious in the best group in town.
Stocks hovered around the flat line in midday trading Monday with the Dow and the S&P 500 slightly down and the Nasdaq inching slightly higher.
For the week of May 11 we await results from Actavis (ACT), Sotheby's (BID), GoDaddy (GDDY), Cisco Systems (CSCO), Macy's (M), Shake Shack (SHAK), Applied Materials (AMAT), and Petrobras (PBR).